3 ms·
Well, it's debatable whether that's "abuse". Companies need to make money to fund research (Shkreli says he's trying to find a "2016 version of Daraprim") and p
by witty_username 10y ago
Well, it's debatable whether that's "abuse". Companies need to make money to fund research (Shkreli says he's trying to find a "2016 version of Daraprim") and pay investors, and if patients aren't hurt, it's not necessarily bad.
- tristanj 10y agoWell, if his actual intent was to help patients who couldn't afford his drug, then he could just sell it to them cheaply. I don't think people would consider that abuse. Instead he chooses make roundabout tax-deductible contributions to a "charity" that covers patients copay's in a legally questionable matter, dumping the cost on their insurer/US government. Is that just some clever money making scheme, or is that abuse? Depends on your perspective. Also, the patients are hurt. Who pays for these drug price hikes? That cost is paid by patients in their higher insurance premiums and American taxpayers in their dollars to Medicaid. Companies that do what Shkreli did make healthcare more expensive for all Americans. The underlying theme is that there are seriously perverse incentives issues in American healthcare that need to be resolved. Until then, some people will make a lot of money.